THE TREATMENT OF COCCIDIOIDOMYCOSIS.

Abstract

Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.

• Authors: Neil M Ampel
• Journal: Revista do Instituto de Medicina Tropical de Sao Paulo (Rev Inst Med Trop Sao Paulo) Vol. 57 Suppl 19 Pg. 51-6 (Sep 2015) ISSN: 1678-9946 [Electronic] Brazil
• PMID: 26465370 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents

Topics

• Antifungal Agents (therapeutic use)
• Coccidioidomycosis (drug therapy)
• Female
• HIV Infections (complications, microbiology)
• Humans
• Lung Diseases, Fungal (drug therapy)
• Pregnancy
• Severity of Illness Index